Home » New trouble at CompuGroup: Is billionaire Frank Gotthardt at risk of a million-dollar debacle?

New trouble at CompuGroup: Is billionaire Frank Gotthardt at risk of a million-dollar debacle?

by admin
New trouble at CompuGroup: Is billionaire Frank Gotthardt at risk of a million-dollar debacle?

With the new hospital information system G3-Clinical, which, according to insiders, has been in development for over ten years, CGM wants to get back on the road to success. IMAGO / Eduard Bopp, picture alliance | CHROME ORANGE / Ernst Weingartner

CompuGroup Medical (CGM) is a well-known player in the German healthcare system. Long-time managing director Frank Gotthardt turned CGM into a billion-dollar company that sells software to hospitals, laboratories and doctors. Most recently he made headlines through his involvement with the right-wing news portal Nius.

Billionaire Gotthardt and the CompuGroup have recently had eventful weeks. In February, the stock price collapsed and there was a restructuring at the company that appeared to include job cuts, Business Insider reported. But Gotthardt and his CompuGroup have a plan: With the new hospital information system G3-Clinical, which, according to insiders, has been in development for over ten years, CGM wants to get back on the road to success. An information system is like the operating system of a clinic; without it, almost nothing works. Hospitals use the software to read insurance cards, plan operating room utilization, or evaluate laboratory data.

Instead of euphoria, G3-Clinical is currently giving some CompuGroup employees headaches and stomachaches. Business Insider spoke to them and they warn that the G3 software, despite a long development period, is causing problems and is not fully ready for the market. The problems were sometimes so great that several hospitals withdrew from their G3 projects. According to insiders, CompuGroup lost millions.

See also  Plasticizer: “You shouldn’t find a substance like that in your body – and we find it”

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy